PIONEER NATURAL RESOURCES CO (PXD)

US7237871071 - Common Stock

207  +1.33 (+0.65%)


Fundamental Rating

5

Overall PXD gets a fundamental rating of 5 out of 10. We evaluated PXD against 378 industry peers in the Oil, Gas & Consumable Fuels industry. PXD has a medium financial health rating, its profitability is only medium as well. PXD is not valued too expensively and it also shows a decent growth rate.




Profitability

Profitability Rating

6

PXD's Return On Assets of 19.50% is amongst the best of the industry. PXD does better than the industry average Return On Assets of 13.72%.
The Piotroski-F score of PXD is 8.00. This is a very strong score and indicates great health and profitability for PXD.

PXD's Return On Equity of 32.24% is in line with the rest of the industry. The industry average Return On Equity is 29.81%.
PXD has a Profit Margin of 30.83%. This is comparable to the industry average of 28.58%.
VS Industry

ROA (19.5%) VS Industry: 68% outperformed.

0.14
2,236.96

ROE (32.24%) VS Industry: 56% outperformed.

0.15
22,783.17

Profit Margin (30.83%) VS Industry: 54% outperformed.

0.19
159.88

Valuation

Valuation Rating

5

With a Price/Earnings Ratio of 7.40, the valuation of PXD can be described as very cheap.
The Forward Price/Earnings Ratio of 8.97 indicates a rather cheap valuation of PXD.
PXD's low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
With a price book ratio of 2.22, PXD is valued correctly.

When comparing the Enterprise Value to EBITDA ratio of PXD to the average industry ratio of 3.64, PXD is valued in line with its industry peers.
Compared to an average industry Price/Earning Ratio of 5.63, PXD is valued slightly more expensive.
Compared to an average industry price book ratio of 1.37, PXD is valued more expensive than its industry peers.
VS Industry

Price/Earnings (7.4) VS Industry: 37% outperformed.

155.75
0.01

Price/Book (2.22) VS Industry: 29% outperformed.

4,866.56
0.04

Enterprise Value/ EBITDA (4.41) VS Industry: 41% outperformed.

235.43
0.36

Growth

Growth Rating

4

The Earnings Per Share has grown by an impressive 47.16% over the past year.
The Earnings Per Share has been growing by 69.80% on average over the past 5 years. This is a very strong growth
Measured over the past 5 years, PXD shows a very strong growth in Revenue. The Revenue has been growing by 35.73% on average per year.
PXD shows a small growth in Revenue. In the last year, the Revenue has grown by 8.97%.

The Revenue is expected to decrease by -0.17% on average over the next 5 years.
Based on estimates for the next 5 years, PXD will show a very negative growth in Earnings Per Share. The EPS will decrease by -11.60% on average per year.
When comparing the EPS growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS69.8% 54.99% 47.16% -28.08% -12.98% -9.73% -11.6%
Revenue35.73% 36.11% 8.97% -6.06% -0.2% -0.17% N/A

Health

Health Rating

5

PXD has an Altman-Z score of 3.71. This indicates that PXD is financially healthy and little risk of bankruptcy at the moment.
PXD is in better financial health than average in its industry. Its Altman-Z score is much better than the industry average of 2.12.
The Piotroski-F score of PXD is 8.00. This is a very strong score and indicates great health and profitability for PXD.
The Debt to Equity ratio of PXD is in line with the industry averages.

PXD has a Current Ratio of 0.88. This is a bad value and indicates that PXD is not financially healthy enough and could expect problems in meeting its short term obligations.
Compared to an average industry Current Ratio of 1.14, PXD is worse placed to pay its short term obligations than its industry peers.
A Quick Ratio of 0.76 indicates that PXD may have some problems paying its short term obligations.
Compared to an average industry Quick Ratio of 0.98, PXD is worse placed to pay its short term obligations than its industry peers.
VS Industry

Debt/Equity (0.23) VS Industry: 50% outperformed.

13.98
0.00

Quick Ratio (0.76) VS Industry: 34% outperformed.

0.00
186.31

Current Ratio (0.88) VS Industry: 35% outperformed.

0.00
186.31

Altman-Z (3.71) VS Industry: 72% outperformed.

-509,914.51
307.34

Dividend

Dividend Rating

7

With a Yearly Dividend Yield of 11.55%, PXD is a good candidate for dividend investing.
PXD's Dividend Yield is rather good when compared to the industry average which is at 5.68. PXD pays more dividend than 86% of the companies in the same industry.
PXD's Dividend Yield is rather good when compared to the S&P500 average which is at 2.71.
The dividend of PXD is nicely growing with an annual growth rate of 216.54%!

PXD has been paying a dividend for at least 10 years, so it has a reliable track record.
The Dividend Rate of PXD has been growing, while earnings will be declining. This means the dividend growth is most likely not sustainable.
PXD pays out 92.54% of its income as dividend. This is not a sustainable payout ratio.
VS Industry

Dividend Yield (11.55%) VS Industry: 86% outperformed.

0.29
63.00

PIONEER NATURAL RESOURCES CO

NYSE:PXD (6/5/2023, 8:50:45 AM)

207

+1.33 (+0.65%)

Chartmill FA Rating
GICS SectorEnergy
GICS IndustryGroupEnergy
GICS IndustryOil, Gas & Consumable Fuels
Earnings (Last)04-26 2023-04-26/amc
Earnings (Next)07-31 2023-07-31/amc
Inst Owners84.6%
Inst Owner Change-6.35%
Ins Owners0.43%
Ins Owner Change4.11%
Market Cap48.38B
Analysts73.71
Price Target257.8 (24.54%)
Dividend
Industry RankSector Rank
Dividend Yield 11.55%
Dividend Growth(5Y)216.54%
DP92.54%
Div Incr Years5
Div Non Decr Years13
Ex-Date05-31 2023-05-31 (2.09)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.23%
Min EPS beat(2)1.48%
Max EPS beat(2)4.99%
EPS beat(4)3
Avg EPS beat(4)2.98%
Min EPS beat(4)-0.51%
Max EPS beat(4)5.94%
Revenue beat(2)2
Avg Revenue beat(2)34.07%
Min Revenue beat(2)23.08%
Max Revenue beat(2)45.05%
Revenue beat(4)4
Avg Revenue beat(4)38.67%
Min Revenue beat(4)23.08%
Max Revenue beat(4)53.72%
PT rev (1m)-2.23%
PT rev (3m)-7.32%
EPS NQ rev (1m)-2.84%
EPS NQ rev (3m)-14.22%
EPS NY rev (1m)0%
EPS NY rev (3m)-20.08%
Revenue NQ rev (1m)0.77%
Revenue NQ rev (3m)2.14%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.26%
Valuation
Industry RankSector Rank
PE 7.4
Fwd PE 8.97
P/S 2.12
P/FCF 7.12
P/OCF 4.37
P/B 2.22
P/tB 2.24
EV/EBITDA 4.41
EPS(TTM)27.96
EY13.51%
EPS(NY)23.09
Fwd EY11.15%
FCF(TTM)29.07
FCFY14.04%
OCF(TTM)47.4
OCFY22.9%
SpS97.69
BVpS93.43
TBVpS92.39
PEG (NY)N/A
PEG (5Y)0.11
Profitability
Industry RankSector Rank
ROA 19.5%
ROE 32.24%
ROIC 22.62%
ROICexc 23.58%
ROICexgc 23.77%
OM 40.88%
PM 30.83%
GM 54.11%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)14.19%
ROIC(5y)12.1%
ROICexc(3y)15.31%
ROICexc(5y)13.05%
ROICexgc(3y)15.44%
ROICexgc(5y)13.2%
ROICexcg growth 3Y44.94%
ROICexcg growth 5Y48.38%
ROICexc growth 3Y45.37%
ROICexc growth 5Y48.77%
OM growth 3Y33.27%
OM growth 5Y30.6%
PM growth 3Y59.18%
PM growth 5Y15.5%
GM growth 3Y9.32%
GM growth 5Y1.44%
F-Score8
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF 0.87
Debt/EBITDA 0.5
Cap/Depr 166.01%
Profit Quality 96.52%
Current Ratio 0.88
Quick Ratio 0.76
Altman-Z 3.71
F-Score8
WACC8.24%
ROIC/WACC2.88
Cap/Depr(3y)131.95%
Cap/Depr(5y)166.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y47.16%
EPS 3Y54.99%
EPS 5Y69.8%
EPS growth Q2Q-32.69%
EPS Next Y-28.08%
EPS Next 2Y-12.98%
EPS Next 3Y-9.73%
EPS Next 5Y-11.6%
Revenue growth 1Y8.97%
Revenue growth 3Y36.11%
Revenue growth 5Y35.73%
Revenue growth Q2Q-25.22%
Revenue Next Year-6.06%
Revenue Next 2Y-0.2%
Revenue Next 3Y-0.17%
Revenue Next 5YN/A
EBIT growth 1Y12.91%
EBIT growth 3Y81.39%
EBIT growth 5Y77.26%
EBIT Next Year-3.53%
EBIT Next 3Y0.06%
EBIT Next 5Y-3.71%
FCF growth 1Y6561.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y577.55%
OCF growth 3Y53.87%
OCF growth 5Y40.15%
Fundamental Stock Screener Links
Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA